Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790463 | 0.94 | CASP3 (0.49) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL28565897 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL28565899 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL17446817 | 0.90 | MDM4 (0.47) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL30758116 | 0.89 | PTPN1 (0.45) | MDM4TP53CASP3PTPN1 | |
| SCHEMBL29812486 | 0.89 | MDM4 (0.43) | MDM4TP53CASP3KMT2APTPN1 | |
| SCHEMBL12744189 | 0.89 | MDM4 (0.52) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL3212833 | 0.89 | MDM4 (0.52) | MDM4TP53CASP3KMT2AKIF11 | |
| SCHEMBL30758115 | 0.88 | PTPN1 (0.45) | MDM4TP53PTPN1 | |
| SCHEMBL18764578 | 0.88 | CASP3 (0.49) | MDM4TP53CASP3KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | claimed |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-02-18 | — | — | US | disclosed |
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312538-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)-7-ETHYLDENE-4,21-BIS(1-METHYL-ETHYL)-2-OXA-12,13-DITHIA-5,8,20,23-TETRAAZABICYCLO [8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE | IL17A, HSD17B7, SULT1E1 | MDM4 1070/4885TP53 4097/4885CASP3 1040/4885 |
| US-10562931-B2 | Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone | SULT1E1, IL17A, TET1 | MDM4 1462/4885TP53 4374/4885CASP3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.